Fox Chase Cancer Center Welcomes Dr. Parth A. Desai

Dr. Desai
Fox Chase Cancer Center is pleased to announce the hiring of Parth A. Desai, MD, as an assistant professor in the Department of Hematology/Oncology.

PHILADELPHIA (September 13, 2023) — Fox Chase Cancer Center is pleased to announce the hiring of Parth A. Desai, MD, as an assistant professor in the Department of Hematology/Oncology. His clinical practice will be based at the department’s rapidly expanding section at Temple University Hospital, where his clinical practice will focus on head and neck cancer, thoracic malignancies, and translational clinical trials.

Prior to joining Fox Chase, Desai was a Clinical Hematology and Oncology Fellow at the National Heart, Lung, and Blood Institute within the National Institutes of Health.

Desai earned his combined Bachelor of Medicine and Bachelor of Surgery degree from Veer Narmad South Gujarat University in Surat, India. He subsequently completed an anatomical and clinical pathology residency at Maulana Azad Medical College in Delhi before coming to the United States.

He then trained briefly in the Department of Hematopathology and the Department of Stem Cell Transplantation/Cellular Therapy at MD Anderson Cancer Center before completing an internal medicine residency at UT Health San Antonio.

In his two decades of scientific training, Desai has undertaken a variety of research projects and has published in numerous peer-reviewed journals on a wide range of topics in hematology and oncology and developmental therapeutics.

His expertise includes designing and running early phase clinical trials, as well as leading translational research using cutting-edge techniques like single cell and spatial transcriptomics, through which he tries to identify novel treatment- and phenotype-related biomarkers and tumor and tumor microenvironment heterogeneity.

He received the 2022 American Society of Clinical Oncology Young Investigator Award and the 2021 National Cancer Institute Director’s Award for his research.

Desai began his tenure at Fox Chase and Temple University Hospital on August 20.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427